Literature DB >> 33841624

IGFBP-1 in cancer: expression, molecular mechanisms, and potential clinical implications.

Yi-Wei Lin1,2, Xue-Fen Weng1,2, Bin-Liang Huang1,2, Hai-Peng Guo3, Yi-Wei Xu1,2, Yu-Hui Peng1,2.   

Abstract

Insulin-like growth factor binding protein-1 (IGFBP-1) belongs to the insulin-like growth factor (IGF) system, which plays an indispensable role in normal growth and development, and in the pathophysiology of various tumors. IGFBP-1 has been shown to be associated with the risk of various tumors, and has a vital function in regulating tumor behaviors such as proliferation, migration, invasion and adhesion through different molecular mechanisms. The biological actions of IGFBP-1 in cancer are found to be related to its phosphorylation state, and the IGF-dependent and -independent mechanisms. In this review, we provided an overview of IGFBP-1 in normal physiology, and its aberrantly expression and the underlying molecular mechanisms in a range of common tumors, as well as discussed the potential clinical implications of IGFBP-1 as diagnostic or prognostic biomarkers in cancer. AJTR
Copyright © 2021.

Entities:  

Keywords:  Insulin-like growth factor-binding protein-1 (IGFBP-1); cancer; clinical implications; expression; molecular mechanisms

Year:  2021        PMID： 33841624      PMCID： PMC8014352     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN： 1943-8141            Impact factor:   4.060


  127 in total

1.  A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women.

Authors:  A Lukanova; P Toniolo; A Akhmedkhanov; C Biessy; N J Haley; R E Shore; E Riboli; S Rinaldi; R Kaaks
Journal:  Int J Cancer       Date:  2001-06-15       Impact factor: 7.396

2.  Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort.

Authors:  Iona Cheng; Kathryn L Penney; Daniel O Stram; Loic Le Marchand; Elena Giorgi; Christopher A Haiman; Laurence N Kolonel; Malcolm Pike; Joel Hirschhorn; Brian E Henderson; Matthew L Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-10       Impact factor: 4.254

Review 3.  Rethinking the war on cancer.

Authors:  Douglas Hanahan
Journal:  Lancet       Date:  2013-12-16       Impact factor: 79.321

4.  IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma.

Authors:  Shintaro Sugita; Yukio Morishita; Junko Kano; Shuichiro Furuya; Aya Shiba-Ishii; Masayuki Noguchi
Journal:  Histopathology       Date:  2011-04-04       Impact factor: 5.087

5.  Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells.

Authors:  H K Yi; P H Hwang; D H Yang; C W Kang; D Y Lee
Journal:  Eur J Cancer       Date:  2001-11       Impact factor: 9.162

6.  Identification and characterization of genes associated with human hepatocellular carcinogenesis.

Authors:  N Kondoh; T Wakatsuki; A Ryo; A Hada; T Aihara; S Horiuchi; N Goseki; O Matsubara; K Takenaka; M Shichita; K Tanaka; M Shuda; M Yamamoto
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

7.  Liver mTOR controls IGF-I bioavailability by regulation of protein kinase CK2 and IGFBP-1 phosphorylation in fetal growth restriction.

Authors:  Majida Abu Shehab; Ian Damerill; Tong Shen; Fredrick J Rosario; Mark Nijland; Peter W Nathanielsz; Amrita Kamat; Thomas Jansson; Madhulika B Gupta
Journal:  Endocrinology       Date:  2014-01-17       Impact factor: 4.736

8.  Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence.

Authors:  J I Jones; A Gockerman; W H Busby; G Wright; D R Clemmons
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

9.  Hypoxia alters phosphorylation status of insulin-like growth factor (IGF)-binding protein-1 and attenuates biological activities of IGF-I in HepG2 cell cultures.

Authors:  Tomonori Tsunawaki; Keiji Sakai; Mai Momomura; Yuichi Wachi; Yukiko Matsuzawa; Mitsutoshi Iwashita
Journal:  J Obstet Gynaecol Res       Date:  2013-07-02       Impact factor: 1.730

Review 10.  Physiology and pathophysiology of IGFBP-1 and IGFBP-2 - consensus and dissent on metabolic control and malignant potential.

Authors:  Andreas Hoeflich; Vincenzo C Russo
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-07-08       Impact factor: 4.690
View more
  3 in total

Review 1.  The Insulin-like Growth Factor System and Colorectal Cancer.

Authors:  Nikola Gligorijević; Zorana Dobrijević; Miloš Šunderić; Dragana Robajac; Danilo Četić; Ana Penezić; Goran Miljuš; Olgica Nedić
Journal:  Life (Basel)       Date:  2022-08-20

2.  A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma.

Authors:  Jung Hyun Jo; Dawoon E Jung; Hee Seung Lee; Soo Been Park; Moon Jae Chung; Jeong Youp Park; Seungmin Bang; Seung Woo Park; Sangsook Cho; Si Young Song
Journal:  Int J Cancer       Date:  2022-06-21       Impact factor: 7.316

3.  Analysis of N6-Methyladenosine RNA Methylation Regulators in Diagnosis and Distinct Molecular Subtypes of Ankylosing Spondylitis.

Authors:  Cheng Zhong; Jia-Hua Liang; Zhen Chen; Li-Ping Zhong; Guo-Dong Sun; Wei-Xing Xie; Dong-Ping Wang; Wen-de Zhuang; Hao-Hua Guo; Da-Xiang Jin; Yu-Ming Li
Journal:  Dis Markers       Date:  2022-09-16       Impact factor: 3.464
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.